- February 26, 2019 Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720
- February 04, 2019 Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994
- January 29, 2019 Spero Therapeutics Announces Initiation of SPR720 Phase 1 Clinical Trial
- January 07, 2019 Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial
- January 07, 2019 Spero Therapeutics Announces Positive Feedback from FDA Pre-Phase 3 Meeting for Oral SPR994 and Submission of IND for SPR994 in cUTI
- November 08, 2018 Spero Therapeutics Announces Third Quarter 2018 Financial Results and Pipeline Overview
- November 05, 2018 Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial
- October 11, 2018 Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR206
- September 27, 2018 Spero Announces Positive SPR994 Phase 1 SAD/MAD Final Results
- September 25, 2018 Spero Therapeutics Announces Presentations at IDWeek 2018
Displaying 11 - 20 of 83 results